China Renaissance Insights: Ongoing Transformation in the Healthcare Sector in 2024 Unlocks Opportunities Across Key Segments

· The numerous landmark overseas licensing deals for Chinese-developed antibody-drug conjugates (ADCs) in 2023 have established ADCs as a new hallmark of Chinese innovative drugs going global. ADCs are a representative example of New Modalities. In recent years, increased capital support for Chinese innovative enterprises has concentrated more resources into New Modalities. Chinese innovative drugs such as ADCs have accumulated substantial expertise, and their teams demonstrate strong execution capabilities, enabling them to seize global opportunities firmly when they arise. It is believed that the future wave of successful global expansion of Chinese innovative drugs will not be limited to ADCs but will also extend to other New Modalities.

·As a global blockbuster drug, GLP-1 has spurred numerous business development (BD) deals among leading pharmaceutical companies. In China, clinical development and transactions related to GLP-1 have also achieved remarkable progress, thereby driving increased interest in the upstream segment of the peptide industry chain.

· The cardiac electrophysiology sector demonstrated encouraging industry progress at the turn of the year. Currently, China has a low penetration rate for cardiac electrophysiology procedures, making it a market with sustained expansion potential. Within this sector, players include MicroPort EP, which has achieved a comprehensive product portfolio layout through years of dedicated R&D, and Mindray, a leading domestic medical device company that rapidly entered the field through inorganic growth via acquisitions. As an emerging technology in cardiac electrophysiology, Pulsed Field Ablation (PFA) achieved a breakthrough in late 2023. Medtronic’s PulseSelect became the first PFA system to receive FDA approval, followed closely by Boston Scientific in January 2024, when its FARAPULSE system gained FDA marketing clearance. This development has undoubtedly boosted the confidence of domestic companies in this field. In the future, as more Chinese enterprises race to obtain regulatory approvals, they will be able to compete on the global stage against international giants, leveraging their independent innovation and technological capabilities.

· In 2023, China’s endoscopy market also witnessed leapfrog development, primarily driven by policy support and breakthroughs in new technologies. Against the backdrop of supportive policies—such as procurement standards favoring domestically produced devices, subsidized loan-interest procurement programs, and the “Thousand Counties Project”—along with shortened registration cycles (with Class III devices reclassified as Class II), domestic manufacturers have seized a historic opportunity to break through. Meanwhile, innovations in foundational technologies (e.g., the integrated breakthrough in fluorescence, 3D, and 4K imaging) have laid the foundation for domestic manufacturers to overtake competitors on the curve.

·In the early years, the market for biopharmaceutical equipment and consumables was dominated by foreign manufacturers. Between 2021 and 2023, extended lead times for imported brands failed to meet the urgent demands of domestic biopharmaceutical companies, CDMOs, and research institutions. In response, a cohort of Chinese enterprises with independent R&D capabilities and product performance comparable to imported brands emerged from the competition, securing a certain share of the market.

As quality and craftsmanship continue to meet the testing and commercial production needs of downstream enterprises, with controllable pricing and after-sales services better aligned with domestic requirements, downstream users have gradually developed habitual usage patterns. Consequently, some outstanding startups in biopharmaceutical equipment and consumables are now capable of competing with imported brands.

In the realm of smart healthcare, brain science has undoubtedly remained a consistent highlight in recent years. We have observed that major economies worldwide are heavily investing in various fundamental research initiatives within this field.

· In the field of neuromodulation, domestic companies have emerged as leaders, with products having obtained regulatory approval and been applied in clinical treatment, while further expanding into new indications.

·In the field of brain-computer interfaces, we have witnessed original Chinese breakthroughs in signal acquisition and signal interpretation.

· In the diagnosis of neurodegenerative diseases, a surge of new technologies for early screening has emerged, bringing the possibility of early intervention for age-related disorders.

· In 2023, numerous multinational pharmaceutical companies announced small nucleic acid drugs as a key R&D focus (e.g., GSK shifted its focus from cell and gene therapy [CGT] to small nucleic acids; Novartis declared small nucleic acids as the cornerstone of its future R&D strategy). Meanwhile, Chinese enterprises have rapidly entered this field in recent years, with leading domestic innovators in small nucleic acid therapeutics having gradually completed technical platform validation and gained prominence on the international stage. In 2024, differentiated small nucleic acid drugs are poised to seize opportunities in both business development (BD) transactions and capital market financing.

·The CNS field also witnessed encouraging breakthroughs in 2023. Alzheimer’s disease has long been referred to as the “R&D black hole” of the pharmaceutical industry; however, Eli Lilly’s Phase 3 clinical trial for donanemab succeeded in May 2023, and Eisai’s lecanemab injection received approval from the NMPA in January 2024. In terms of transactions, numerous multinational corporations (MNCs) announced high-value acquisitions of neuroscience companies in 2023. The global R&D progress and landmark deals in the CNS sector have undoubtedly served as a significant boost to domestic Chinese CNS enterprises, driving their further development.

·In the field of AI-driven drug discovery (AIDD), collaborations between pharmaceutical companies and investment and financing activities have continued to heat up in recent years, with several large-scale transactions occurring in 2023. Advanced chip manufacturer NVIDIA made significant investments in AI-powered drug discovery in 2023, investing in nine companies, which indirectly underscores its confidence in the future potential of AIDD. In the AIDD sector, continuous technological iterations and expanding application areas will continue to bring opportunities and breakthroughs. For instance, with the emergence of ChatGPT, the generative AI boom has been ignited, and this new technology is undergoing ongoing trials and validation in applications such as target discovery and molecular generation.

· China has currently taken the initiative in the low- to mid-end biomedical materials market, but high-end materials still rely on imports. There are many challenges in the research and development and large-scale production of new materials. However, in 2023, we saw a group of biomedical material companies rise to the challenge, achieving innovative breakthroughs from biological material technology platforms to the design and development of clinical products. As these products were gradually registered, approved, and commercialized, they also attracted significant capital interest. It is believed that in 2024, more domestic high-end material companies will catch up, laying a solid foundation for the development of innovative Chinese-made devices.

· The ophthalmology sector has long been regarded by investors as a “golden track.” Multiple ophthalmic service companies have successfully gone public, and we have also observed sustained momentum among emerging innovators in ophthalmic pharmaceuticals and medical devices within the primary market. Domestic substitution is underway to varying degrees for ophthalmic equipment, spanning both diagnostic and therapeutic products. In the area of ophthalmic consumables, domestic innovative products have achieved new breakthroughs, such as the launch of multifocal cataract intraocular lenses (IOLs), iterative advancements in extended depth-of-focus IOLs, and myopic refractive IOLs that are poised to compete with implantable collamer lenses (ICLs) in the refractive correction market. Looking ahead, platform-type ophthalmology enterprises that command independent innovation capabilities and maintain robust product pipelines will be well-positioned for a highly promising future.

·In 2023, the primary market for the medical aesthetics industry witnessed broad-based growth, with high-potential niche segments primarily including injectable products and providers of non-invasive devices. Drawing on the development trajectory of the medical device industry, the import substitution of medical aesthetic equipment has also reached a critical juncture. Listed companies are actively positioning themselves in this space, employing diverse strategies ranging from mergers and acquisitions and financing to product licensing partnerships, thereby leveraging abundant financial and strategic channel resources. We anticipate that this trend will continue into 2024.

· In the field of biomedical materials, Ruining Biology is a typical representative in the niche segment of high-end biomedical materials. With material technology as its core, the company has developed highly competitive differentiated products. Leveraging its independently developed, internationally leading medical hydrogel technology platform, Ruining Biology has created multiple global First/Best-in-Class products, providing systematic solutions for urgent clinical needs such as radiation protection during tumor radiotherapy, tumor embolization, and tissue filling. Its advanced clinical progress serves multiple departments including radiation oncology, gynecology, urology, and digestive surgery. The company recently completed a Series B financing round of nearly RMB 100 million.

· In the field of major diseases, it is essential to highlight Lisheng Pharmaceutical, the only leading enterprise in China that currently integrates R&D of innovative complex formulations with efficient automated production. As an integrated pharmaceutical company covering R&D, comprehensive process development, and large-scale manufacturing, Lisheng has established China’s first FDA-certified BFS (Blow-Fill-Seal) sterile filling production platform, making it a scarce and valuable asset. Leveraging this platform, its proprietary pipeline targets major disease areas such as respiratory and ophthalmic conditions, while its CDMO/CMO services provide stable cash flow and self-sustaining revenue capabilities. Furthermore, the founder’s over 30 years of accumulated expertise in innovative drug R&D further raise the company’s growth ceiling. We are currently providing Series B financing advisory services for Lisheng Pharmaceutical.

· In the field of emerging technologies, we remain optimistic about the intellectual synergy between new technologies and the traditional pharmaceutical industry, as well as its potential for industrial innovation. Triastek has been a client deeply served by China Renaissance across multiple financing rounds, standing out in the track of innovative R&D technology platforms. Leveraging its disruptive digital formulation technology, globally leading 3D printing technology for pharmaceuticals, and continuous manufacturing capabilities, the company has achieved breakthrough innovations in complex drug delivery, development, and production methods. Triastek also completed its Pre-C round of financing in 2023.

· In addition, we continue to closely monitor spin-off financing opportunities for listed companies. Leveraging the industrial strength of these companies and the proven track records of their core management teams, we incubate and cultivate high-growth subsidiary business units. This includes transaction opportunities such as the carve-out and divestiture of more mature business segments within listed companies, as well as the spin-off and independent development of innovative businesses.

· Precision medicine, as a crucial approach to enhancing diagnostic and therapeutic standards and achieving personalized healthcare, is garnering increasing attention. Molecular imaging technology is regarded as one of the top ten medical science frontiers with the greatest development potential, and its emergence has brought new opportunities for the advancement of precision medicine.

For instance, DPM has made in-depth strategic investments in the field of precision surgery by leveraging technologies such as optical molecular imaging fluorescence endoscopy. It has established a “device + consumables” portfolio centered on fluorescence endoscopes and complemented by molecular imaging contrast agents. Meanwhile, leveraging its internationally leading technology platform, the company is further enriching its product matrix with offerings in artificial intelligence and magnetic nanoparticles, among others. The company has entered into a deep strategic partnership with Johnson & Johnson China and recently successfully completed its Series C financing round, raising over RMB 200 million.

· Major economies worldwide have positioned brain initiatives as strategic national policies, with brain-computer interfaces (BCIs), as the foundational core technology of these initiatives, poised to shine. The ultimate goal of BCIs is to maximize the utilization of the brain while minimizing neural damage. Their development spans multiple disciplines, including microelectronics, medical devices, semiconductors, and neuroscience. In recent years, China has witnessed significant advancements in these foundational fields, giving rise to leading BCI companies.

For example, BrainCo leverages flexible brain-computer interface (BCI) technology to protect and explore the brain, focusing on the research and development of invasive BCI devices—a field characterized by extremely high technical barriers and global scarcity. The company has achieved breakthroughs in core technologies and developed key components, thereby establishing a fully integrated industry chain.

Furthermore, NeuroXess is the first company globally to obtain ethical approval for clinical trials of flexible brain-computer interfaces (BCIs). Its research progress, animal studies, and clinical trials have achieved breakthroughs and validation ahead of peers, paving the way for rapid commercialization. Leveraging the industry’s most comprehensive BCI platform ecosystem, the company will build an open ecosystem in the future, continuously iterating and upgrading its scalable platform to collaborate on developing downstream applications across multiple fields for scientific research and medical use.